Phenogen Sciences has launched the BREVAGen genetic test for assessing non-familial breast cancer risk. The BREVAGen breast cancer risk stratification test is a genetic test panel that examines a patient’s blood sample to detect the absence or presence of certain common genetic variations (SNPs) associated with an increased risk for developing breast cancer.
The test is designed to help physicians assess aggregate breast cancer risk from these genetic markers, plus factors from a standard clinical assessment based on a patient’s family and personal history. The BREVAGen test may be useful for women at intermediate risk of developing breast cancer, including those who have undergone breast biopsies, as the test will provide information that can help physicians recommend alternative courses of action, such as more vigilant, targeted surveillance or preventive therapy, on a patient-by-patient basis.
For more information visit www.gtglabs.com.